A pproximately 30,000 Americans have cystic fibrosis (CF). It is the most common severe recessive genetic disorder among Caucasians. 1 The disease is caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a transmembrane chloride ion channel. One mutation, ⌬F508, causes ϳ70% of CF cases (ϳ50% of CF patients are homozygous for this mutation) in Caucasian populations. Other mutations are far rarer. Mutation and carrier rates vary by ethnicity. CFTR mutations lead to excessively thick and sticky mucus and, as a result, to frequent infections in the lungs. Approximately 90% of CF patients die from obstructive lung disease. 2, 3 As of 2006, half of all CF patients were expected to survive until 36.9 years of age. 4 Currently, there is no cure for CF. Therapies to treat the symptoms of the disease include movement and clearing of mucus in the lungs, antibiotic treatment of infections, and diet and pancreatic enzyme replacement to improve nutrition. 5 Lung transplants are an option for adult and pediatric patients, although the procedure's utility for children is unclear. 6, 7 Early detection through newborn screening can reduce deaths due to CF and alert parents and doctors to the need for disease management. 8 Carrier screening also has implications for reproductive decisions. Hence, the American College of Medical Genetics (ACMG) endorses carrier screening based on testing for CFTR mutations and newborn screening, which uses DNA testing if high levels of the enzyme immunoreactive trypsinogen (IRT) are detected. 9, 10 CF was chosen as a case study specifically because nonexclusive licensing practices for the gene and its mutations allow for a rough comparison with other genes that are exclusively licensed. The University of Michigan, the Hospital for Sick Children (HSC) in Toronto, and the Johns Hopkins University (JHU) hold patents covering CFTR mutations and methods for detecting them. The University of Michigan's patent portfolio includes the important ⌬F508 mutation. Currently, 63 laboratories in the United States test for CFTR gene mutations. 11 This is possible in part because the University of Michigan, HSC, and JHU license their respective patents nonexclusively.
A survey of laboratories' prices for CF genetic testing, a review of literature on cost-effectiveness of CF tests, and the developing market for CF testing provide no evidence that patents have significantly hindered access to genetic tests for CF or prevented financially cost-effective screening. Current licensing practices seem to facilitate both academic research and commercialization of products.
BACKGROUND
Approximately 30,000 Americans have CF, making it the most common severe recessive genetic disorder among Caucasians. 1 Carrier rates vary by ethnicity. According to the American College of Obstetricians and Gynecologists (ACOG): 3 The CFTR gene encodes a transmembrane chloride ion channel, mutations of which result in defective movements of materials through membranes and accumulation of excessively thick and sticky mucus throughout the body. CF affects multiple bodily functions including breathing, digestion, and reproduction. Symptoms include chronic pulmonary disease, pancreatic exocrine insufficiency, reproductive disorders, and elevated sweat chloride levels. Because CF patients cannot adequately clear their airways of the mucus buildup, they wheeze, cough, and suffer from repeated lung infections and other pulmonary pathologies. Approximately 90% of CF patients die because of obstructive lung disease. The thick, sticky mucus found in CF patients also accumulates in the pancreas, thus preventing digestive enzymes from reaching the small intestine and leading to poor digestion, retarded growth, and persistent diarrhea. 1, 11 "Almost all males with CF are infertile due to congenital malformation of the reproductive tract." 2 According to a consensus panel convened by the Cystic Fibrosis Foundation, "the diagnosis of CF should be based on the presence of one or more characteristic phenotypic features, a history of CF in a sibling, or a positive newborn screening test result plus laboratory evidence of a CFTR abnormality as documented by elevated sweat chloride concentration, or identification of mutations in each CFTR gene known to cause CF or in vivo demonstration of characteristic abnormalities in ion transport across the nasal epithelium." 12 Although few children born with CF in the 1950s could expect to survive to attend school, by 2006, half of all CF patients were expected to survive to 36.9 years. 4 Seventy-one percent of patients are diagnosed within 1 year of birth; 92% of patients are diagnosed by the time they are 10 years old. 12 Currently, there is no cure for CF, although research into normalizing the mutated ⌬F508 CFTR protein product using small molecule pharmaceuticals continues. Physical therapy and medications can enhance patients' length and quality of life. Current therapies include movement and clearing of mucus in the lungs, pharmaceutical treatment of infections, and diet and pancreatic enzyme replacement to improve nutrition. 5 Lung transplants are an option (but not a cure) for adult patients with damaged lungs. 6 Lung transplants for children are performed, but their clinical utility is unclear. 7 Early detection through newborn screening can reduce deaths caused by CF and alert parents and doctors to the need for disease management. 8 Carrier screening also informs prospective parents about their risks of having an affected child. Screening and diagnostic methods, including genetic tests, are discussed in more detail below.
GENE DISCOVERY
Researchers have used a plethora of gene identification methodologies to search for and map the CF gene. The nearly 40-year hunt for the CF gene began in the 1950s. Using linkage analysis, researchers studied whether the CF gene was linked to blood groups but were unsuccessful. 13, 14 A major difficulty in identifying the CF gene was the lack of cytologically detectable chromosome rearrangements or deletions. Such large-scale DNA changes greatly facilitated the positional cloning of some other human disease genes.
In the 1980s, new technologies were applied to search for the CF gene. Researchers used restriction fragment length polymorphisms (RFLPs, which reflect sequence differences in DNA sites that can be cleaved by restriction enzymes) for linkage analysis to establish the approximate chromosomal location of genes. In 1985, Tsui et al. 15 reported that an uncharacterized RFLP marker, DOCRI-917, was linked to the CF gene in 39 families with CF-affected children. It took 4 years of intensive effort by many laboratories to move from this initial linkage to find the mutated gene. Wainwright et al. 16 reported a tight linkage between the CF locus and another chromosome 7 probe, pJ3.11. White et al. 17 independently mapped the gene to chromosome 7. Tsui and coworkers, using genetic linkage analysis, further localized the DOCRI-917 on human chromosome 7, but additional studies were needed to determine the exact location of the gene. 18, 19 Zengerling et al. 20 in 1987, used human-mouse cell hybrids to narrow the search to a small segment of chromosome 7. Shortly afterward, Estivill et al. 21 reported a potential breakthrough in disclosing a candidate cDNA for the CF gene, but individuals with CF did not have mutations in that candidate gene. Rommens et al. 22 closed the gap further, mapping two more probes (D78122 and D7S340) to a location between two markers known to flank the CF gene, MET and D7S38. Finally, in 1989, Drs. Tsui and John Riordan and coworkers from the HSC and Dr. Francis Collins and fellow researchers, then at the University of Michigan, identified the gene encoding the CFTR. [23] [24] [25] This was the first time a human disease gene had been identified solely on the basis of its chromosomal location, without biochemical clues or the availability of visible cytogenetic rearrangements to guide the search. Although the identification of markers that flanked the gene did not indicate the gene's exact location, the discovery of these markers did provide a starting point for novel DNA-cloning strategies specifically developed to locate the CFTR gene. These strategies included chromosome jumping from the flanking markers, cloning of DNA fragments from a defined physical region, a combination of somatic cell hybrid and molecular cloning techniques designed to isolate DNA fragments, chromosome microdissection and cloning, and saturation cloning of a large number of DNA markers from the 7q31 region. These techniques were pioneered in the hunt for the CF gene because it was a relatively common disease known to have a single-gene cause and because the gene's location was approximately known.
The CFTR gene
The CFTR gene encodes a protein that regulates the flow of chloride ions through membranes. Mutations in CFTR alter protein function, which in turn causes the symptoms of CF in afflicted patients. Because different mutations alter protein function in different ways and to different degrees, there are wide variations in the severity of the clinical syndrome. To date, scientists have found Ͼ1500 mutations in the CFTR gene. 1, 26 ⌬F508, a deletion of three nucleotides in DNA, causes the protein to lack the amino acid phenylalanine (F) at position 508. This one mutation accounts for 70% of CF chromosomes worldwide and 90% of CF patients in the United States. Individuals homozygous for ⌬F508 (ϳ50% of patients) have the most severe form of CF. 2, 27 Differences in the frequency of various mutations among ethnic groups complicate analysis of genetic testing. The Foundation for Blood Research reports: "A different mutation [than ⌬F508] is the main cause of cystic fibrosis in Ashkenazi Jews. Half of Ashkenazi Jewish carriers of cystic fibrosis have the W1282X mutation (rarely found in non-Jewish carriers), whereas less than one-third have the [⌬F508] mutation. In other populations, no single mutation accounts for a dominant proportion." 28 Certain CFTR mutations are known to result in a milder clinical syndrome. Some of these spare the pancreatic involvement (and are, thus, called pancreatic sufficient), and even milder mutations may result in only isolated male infertility because of congenital bilateral absence of the vas deferens. However, the severity of lung disease is not entirely predictable on the basis of genotype. As Grody et al. 26 note, "It has been clear since the cloning of the gene that CFTR is a very complex genetic element, replete with an ever-growing number of iden-tified mutations and variants and subject to modification in its phenotypic effects by internal polymorphisms and distant gene loci. It has been a major undertaking just to characterize the molecular and functional effects of the more common mutations. When it comes to rare variants . . . much less is known . . .. The potential for misattribution of effects and for false assumptions is manifest." Thus, there is much to be learned that may affect how tests are licensed or conducted, making the relationship between the intellectual property and clinical data described below subject to continual revision. August 18, 1989 .) This family of United States and foreign patent applications covered the sequence of the normal and ⌬F508 mutant cDNAs, genetic testing, the normal and mutant CFTR proteins, and vectors and cell lines expressing the normal and mutant CFTR genes.
PATENTS
The United States Patent and Trademark Office declared a patent interference after receiving a patent application from Genzyme Corporation, with Richard Gregory as the first inventor. The Genzyme application claimed the sequence of the CFTR cDNA and rights to the CFTR-containing vector, which overlapped with claims in the Michigan-HSC patent applications. Subsequently, Genzyme argued that Tsui et al. failed to provide a written description of the manner and process for their inventions (United States Patent and Trademark Office interferences 103,882; 103,933; and 104,228). The interference proceedings went on for 10 years and were resolved in part in Tsui's favor in 2002. 29 -31 The Tsui patents covering both the wild-type CFTR cDNA sequence and ⌬F508 mutant sequences (US 6,984,487) and the CFTR protein sequence (US 6,730,777) were granted. Genzyme was granted patent US 5,876,974, which covers methods for producing the CFTR cDNA. In 2006, Genzyme was granted US 7,118,911, which covers vectors for producing the CFTR cDNA (see Appendix 1). Dr. Ritchie confirmed that the interference was a time-consuming and expensive process. However, a licensee that was developing a CF therapeutic funded a majority of the interference costs for the University of Michigan and HSC. Importantly, one of Tsui's patent applications covering genetic testing methods for the ⌬F508 mutation was not included in this interference and issued as US 5,776,677 (the Ј677 patent) on July 7, 1998. Thus, licensing of this particular patent was not affected by the interference. 11 Dr. Ritchie recalled only one instance in the past 10 years that dealt with potentially infringing activity. A licensee advised the University of Michigan of an unlicensed company advertising CF diagnostic services to consumers. Dr. Ritchie contacted the company and verbally informed it of the 677 patent and asked if the company was interested in taking a license. Because the company in question "dropped it" and presumably ceased offering diagnostic services, the matter was not taken to the level of formal, written communication, or legal action (D. Ritchie, personal communication, 2008) .
LICENSING
Licensing practices are especially important because CF tests are essential in newborn screening and population screening for carriers. As Grody et al. 26 state, "Perceiving a large market as CF screening was declared standard of care for the entire population, the first of any commercial consequence in the history of molecular genetics, reagent and equipment vendors quickly developed and began marketing test platforms. Indeed, virtually overnight CF became the flagship test product offered by many established and start-up companies." Currently, the Food and Drug Administration (FDA) has approved at least two diagnostic "kits" for CF, and other companies are proceeding through the regulatory process for producing and selling diagnostic devices.
For example, one FDA-approved diagnostic kit is the Luminex Kit, which includes intellectual property held by HSC and Johns Hopkins. 38 The HSC and Hopkins patents cover mutations other than the ⌬F508 mutation (see Appendix 1) . Two of the four mutations covered by Hopkins patent US 5,407,796 are included in the ACMG's currently recommended list of mutations to test. Laboratories that test for the ⌬F508 mutation and the mutations patented by HSC and Hopkins presumably must obtain licenses from all three patent-holding institutions (Michigan-HSC, HSC, and Johns Hopkins) because "valuation" of each of the mutations is always a negotiable topic and each institution is best able to defend its valuation philosophy.
Another major player in CF testing is Ambry Genetics, which advertises several proprietary CF tests. The advertisements state that Ambry has "analyzed the complete CF gene in more than 10,000 patient samples." 39 Other manufacturers are preparing FDA-approved diagnostic tests to compete in the CF testing and screening markets, further increasing the probable number of licensees of the University of Michigan, HSC, and Hopkins patents. In spring 2007, Nanogen announced that "it has submitted the 510(K) [premarket notification] to FDA for its Cystic Fibrosis Kit and NanoChip 400 microarray system." 40 The kit tests for the ACMG-recommended 23 mutations. 40 In January 2007, Third Wave also submitted a 510(K) form for its CF test, which is "intended to provide information to determine CF carrier status in adults, as an aid in newborn screening and in confirmatory diagnostic testing in newborns and children." 41 The FDA has since approved the test for diagnostic use. 42 On June 9, 2008, Third Wave and Hologic announced Hologic's purchase of Third Wave for $580 million cash. In a conference call, Hologic's Chairman said that one reason for the acquisition was that the CF test "will be a natural complement to our full-term preterm birth product which is sold by our OB/Gyn sales force." 42 Although genetic tests for human papilloma virus were described as a more important reason for the acquisition than the CF testing platform, it seems that Third Wave's ability to license and use intellectual property including CF mutations was an asset. Table 1 shows the test panel currently recommended by the ACMG with annotations describing how the relevant intellectual property is distributed. 9 The clinical importance of the chart is discussed. The mutation list below is a current standard of care that the test market aims to meet or exceed.
More recently, several nonprofit institutions that fund forprofits doing research on CF and drug development for diarrhea have approached the University of Michigan and HSC about licensing rights to develop and use screening assays for small molecule drug discovery. Because much of the original research leading to the discovery of the CFTR gene was funded by two nonprofit organizations, the Cystic Fibrosis Foundation and the Howard Hughes Medical Institute, specific licenses were developed for the Cystic Fibrosis Foundation Therapeutics, Inc., and for One World Health, whose missions, in part, are to ensure broad access to medical technologies. This is a new type of "research" license for the use of CFTR-related patents and grants both Cystic Fibrosis Foundation Therapeutics, Inc., and One World Health rights to sublicense appropriate patents covering research tools such as the CFTR gene sequence and cell lines containing either the normal gene or the ⌬F508 mutant to for-profit companies conducting research. Applicable research includes screening small-molecule libraries to produce therapeutic CF or antidiarrheal drugs (D. Ritchie, personal communication, 2007). The parties developed this promising licensing strategy to reduce transaction costs and facilitate research on new therapeutic drugs for treating these devastating conditions. Success could be especially beneficial in resource-poor regions of the world where diarrheal diseases are endemic. According to Dr. Ritchie, the University of Michigan and HSC will receive a small sublicense fee whenever a sublicense is granted but will not receive any royalties from sales of the final drug products. In other words, this license does not give the University of Michigan or HSC any "reach through" rights because they have only licensed access to research tools.
TESTING PRACTICES FOR CF

Newborn screening
Early detection of CF is important to improve disease management. Farrell et al. 43 found that "early diagnosis of CF through neonatal screening combined with aggressive nutritional therapy can result in significantly enhanced long-term nutritional status." In 2005, the CDC released recommendations on newborn screening for CF and indicated several benefits from newborn screening both for disease management and improving quality of life. 44, 45 In a review in 2006, Grosse et al. 8 found that newborn screening can reduce childhood mortality from CF.
In May 2006, the ACMG published a report from its Newborn Screening Expert Group, which included academic experts, government officials, professional medical organization representatives, and patient advocates. The report recommended that newborns undergo testing for CF and 28 other conditions in state newborn screening programs. The report considered the model of initial screening for unusually high levels of the enzyme IRT, followed by a second IRT test, and then a DNA test if necessary. 46 In a letter to DHHS Secretary Leavitt, the Secretary's Advisory Committee on Heritable Disorders and Genetic Diseases in Children "strongly and unanimously recommends that the Secretary initiate appropriate action to facilitate adoption of the ACMG recommended screening panel [which includes CF] by every State newborn screening program." 47 The ACMG's guidelines for newborn screening call for testing of levels of the IRT enzyme, which if unusually high are indicative of CF, followed by a repeat IRT test or DNA testing and a sweat test for elevated chloride levels that will confirm a diagnosis of CF. In the screening protocol either a positive repeat of the IRT test or a positive DNA test for one of 23 mutations leads to a sweat chloride test for confirmation. 10 Although comprehensive data about states' testing practices are not available, some information is available from the National Newborn Screening Information System. According to their 2008 report on CF screening, at least 28 states include CF in their newborn screening programs. All of those states test IRT in the first round of testing; 17 of them use a DNA test if IRT levels indicate a second round of testing is required. At least 7 of those DNA tests are based on testing for 38 to 43 mutations (2008 data from National Newborn Screening Information System, on file with authors). As of November 11, 2009 , all states except Texas conduct universal newborn screening, and Texas plans to begin mandatory universal screening on December 1, 2009. 48 Given the spate of recommendations on CF testing, newborn screening for CF seems likely to continue evolving rapidly.
Carrier testing
ACMG guidelines and update (2001 and 2004)
Current guidelines for genetic testing for CF mutation carriers were developed in response to a 1997 NIH report, which stated, "Genetic testing for CF should be offered to adults with a positive family history of CF, to partners of people with CF, to couples currently planning a pregnancy, and to couples seeking prenatal care." 49 In 2001, the ACMG published recommendations on CF carrier screening. In 2001, the ACOG, the ACMG, and the NIH Steering Committee incorporated those recommendations into a set of clinical guidelines and educational material sent to clinicians. The ACMG called for screening to be offered to a more specific population of "non-Jewish Caucasians and Ashkenazi Jews." 50 The ACMG recommended using a pan-ethnic CFTR panel of 25 CFTR mutations, all of which occurred in at least 0.1% in the general US population. In 2004, additional data on the rarity of two mutations persuaded the ACMG to remove them from the panel. 9, 50 The updated panel will detect mutations in 94% of Ashkenazi Jewish carriers, 88% of non-Hispanic Caucasian carriers, 72% of Hispanic Americans, 65% of African Americans, and 49% of Asian Americans. 3 As of 2006, the ACMG still endorses the updated panel of 23 mutations. 51 In its 2001 recommendations, the ACMG advised providers that they should not routinely offer testing for additional mutations. However, providers could disclose the existence of such extended panels to inquiring patients and use such panels on an ad hoc basis. Couples in which one or both partners are positive, those with family history of CF, or men found to have mutations associated with infertility require further genetic counseling or additional testing strategies. In those cases, the ACMG encouraged clinicians to direct patients to visit genetics centers. Also, "patients diagnosed with CF . . . should be referred [directly] to a genetics center for appropriate testing and counseling." 50 Although acknowledging that "testing will often occur in the prenatal setting," the ACMG urged "preconception testing . . . whenever possible." 50 The ACMG also recommended that providers make carrier testing available to couples whose ethnic background reduces their risk for CF but also might have CF mutations of lower frequency in existing databases, because current data are based primarily on Caucasian population studies. The ACMG specifically indicated that "Asian-Americans and Native Americans without significant Caucasian admixture should be informed of the rarity of the disease and the very low yield of the test in their respective populations." 50 Similarly, the ACMG recommended that "testing should be made available [but not offered] to African-Americans, recognizing that only about 50% of at-risk couples will be detected." 50 The corollary is that CF screening and testing in populations outside Europe and North American might require better data about CFTR mutations in non-Caucasian populations.
For Ashkenazi Jewish and Caucasian couples of Northern European descent, the ACMG recommended couple-based testing. In couple-based testing or concurrent testing, the laboratory collects and tests a sample from each partner and fully discloses the results to each partner. In populations in which individuals are less likely to be CF mutation carriers or in cases where testing both partners simultaneously is difficult, providers can consider testing one person and then only testing the second if the first has a mutation (sequential testing). "In general, the individual provider or center should choose whichever method they feel is most appropriate or practical." 50 
ACOG screening recommendations (2005)
In December 2005, the ACOG updated its recommendations. ACOG expressed concern that "most obstetricians are offering [CF] carrier screening to their pregnant patients . . . [but] significantly fewer obstetrician-gynecologists offer nonpregnant patients [CF] carrier screening unless a patient requests the information or has a family history." 3 Noting how "difficult [it] is to assign a single ethnicity" to a patient, the ACOG nonetheless recommended increasing the scope of carrier testing. "It is reasonable to offer CF Carrier screening to all couples regardless of race or ethnicity as an alternative to selective screening." 3 This recommendation comes with the caveat that providers should be clear about the impact of ethnicity on carrier risk and test sensitivity. Further, "cystic fibrosis carrier screening should be offered before conception or early in pregnancy when both partners are of Caucasian, European, or Ashkenazi Jewish ethnicity. Patients may elect to use either sequential or concurrent carrier screening; the latter option may be preferred if there are time constraints for decisions regarding prenatal diagnostic testing or termination of the affected pregnancy. Individuals who have a reproductive partner with cystic fibrosis or congenital bilateral absence of the vas deferens may benefit from screening with an expanded panel of mutations or, in some cases, a complete analysis of the CFTR gene by sequencing." 3
Prenatal diagnostic testing
ACMG guidelines and update (2002 and 2006)
The 2006 updated ACMG Standards and Guidelines for CFTR Mutation Testing state that prenatal CFTR mutation testing is indicated if there is a "positive family history," "a CF mutation in both partners," or an "echogenic bowel in fetus during second trimester." 51 The test can be performed using "both direct and cultured amniotic fluid cells and chorionic villus samples." 51 The parents should both be tested before the fetus. Because of the significance of the results, "The laboratory must . . . provide referring professionals with appropriate instructions. Laboratories must have a prenatal follow-up program in place to verify diagnostic accuracy." 51 The 2006 recommendations also note that prenatal diagnostic testing typically requires a larger mutation panel than carrier screening. "A larger number of mutations (Ͼ23) is generally appropriate for diagnostic testing in order to achieve the highest possible clinical sensitivity, but care should be taken to ensure that the penetrance of tested mutations is known." 51 Finally, "A positive prenatal diagnostic test result is considered to be definitive rather than predictive since the penetrances for these 23 mutations are known to be high." 51 
Preimplantation genetic diagnosis
ACMG guidelines and update (2002 and 2006)
In October 2002, the ACMG Laboratory Quality Assurance Committee released Standards and Guidelines for CFTR Mutation Testing, intended as an educational resource for clinical laboratory geneticists. 52 Preimplantation testing is indicated for CF in the 2002 guidelines and the 2006 updated version. 51 Despite lingering technical concerns about performing DNA assays using a relatively small sample, preimplantation diagnosis for CF was first reported in 1992 and has continued to occur. 53 
Diagnostic testing
The updated 2006 ACMG Standards and Guidelines for CFTR Mutation Testing note that CF mutation testing is indicated for diagnostic purposes when there is a possible or definite clinical diagnosis of CF, when an infant presents with meconium ileus (excessively thick bowel movements immediately after birth), or when a male presents with congenital bilateral absence of the vas deferens. Because this mutation testing is done for diagnostic rather than screening purposes, laboratories may need to expand the mutation panel beyond the core 23 mutations used in carrier testing. 51 The ACOG adds that although gene sequencing "is not appropriate for routine carrier screening," it is acceptable "for patients with cystic fibrosis, a family history of cystic fibrosis, infertile males with congenital bilateral absence of the vas deferens, or a positive newborn screening test result when mutation testing using an expanded panel of mutations has a negative result." 3 More recently, Grody and others involved in the ACMG statements have expressed personal concern about the use of a rapidly increasing number of mutations and gene sequencing options. This trend is not necessarily in patients' best interest because of limited knowledge about CF's genetic basis. "[A] large number of mutations selected for expanded panels . . . were chosen because the testing laboratory happened to stumble upon one, or read about it in a research or clinical paper whose researcher or clinician author had likewise stumbled upon it. In other words, these are very rare events, arbitrary almost to the point of randomness." 26 Given the frequency with which guidelines have been released and debated, medical consensus and guidelines for diagnostic testing and other testing forms seem likely to evolve.
COST OF CF GENETIC TESTS
Prices for CF genetic tests were obtained from 12 laboratories. Prices are those charged to insurance companies, except for Quest Diagnostics and JHU DNA Diagnostic Laboratory, which chose to provide out-of-pocket costs for patients who do not use insurance to cover the test. Sequencing prices are discussed below (See Table 2 
With those caveats noted, the price range for CFTR gene sequencing among nonprofit institutions ($40 -$86.23 for each sequence targeted for amplification or amplicon) is higher than the per-amplicon price range of nonprofits' sequencing of the colorectal cancer gene APC ($28.57-$39.88). However, the price per amplicon for CFTR sequencing is comparable with that of nonprofit laboratories' prices ($30.00 -$77.44/amplicon) for sequencing MLH1, MSH2, and MSH6 genes. 58 This comparison among the prices of sequencing different genes is only an approximation. The fact that Baylor College of Medicine, City of Hope, and Harvard perform both colorectal cancer and CF testing and that colorectal cancer genes are also licensed nonexclusively by nonprofits makes the comparison worth noting. Specifically, the same laboratories performing these two tests presumably incur similar overhead costs. Also, because JHU has patents on certain CFTR mutations and APC and MSH2, at least one common actor is involved in licensing intellectual property associated with colorectal cancer testing and CF testing. Sequencing the colorectal cancer genes and CFTR, on a price-per-amplicon basis, is comparable with sequencing the BRCA1 and BRCA2 genes, for which the sole provider Myriad Genetics charges $38.05 per amplicon. 58 That is, CF and colorectal cancer genes cost slightly more per amplicon to sequence at nonprofit academic institutions than BRCA1 and BRCA2 genes at Myriad Genetics, the single forprofit provider. 58 
COST-EFFECTIVENESS OF CF SCREENING TESTS
Cost-effectiveness of CF testing is a concern for payers and consumers. If testing is cost-effective at a certain price and CF tests that analyze patented mutations are available at or below that price, then CF licensing practices at least do not preclude cost-effective testing. As the CF testing market continues to develop, licensing practices may also have to evolve, although changes are contingent on current licensing terms until they expire or are renegotiated.
The first step in analyzing cost-effectiveness for CF testing is to determine the financial cost of treating the disease. According to the 1997 NIH Consensus Development Conference Report: Other studies give varying US estimates of the lifetime financial cost of medical care for a CF patient, ranging from $220,000 to $844,000 (1996 dollars). 59 The next step is to compare that cost to the cost of various tests. Evidence is available for carrier and prenatal screening and, to a much lesser extent, preimplantation genetic diagnosis (PGD).
Carrier and prenatal screening
When analyzing cost-effectiveness of CF carrier testing, costs beyond providing the actual test include obtaining informed consent, providing educational and counseling services, and administrative costs. To assess the cost-effectiveness of universal prenatal screening, a number of additional factors must be considered including the number of participants, the population rate of CF carriers, the number of couples with an affected fetus who would choose to terminate the pregnancy, the number of children couples may desire, and the testing method used.
In one study by Asch et al., 60 the costs and clinical outcomes of 16 strategies for CF carrier screening were evaluated using a model of 500,000 pregnancies in a population of only European descent. Asch et al. found that a sequential screening approach minimized the cost of averting CF births. With this approach, the first partner was screened with a test for the ⌬F508 mutation and five other common mutations known at the time. This panel, covering fewer mutations than the ACMG now recommends, was modeled as identifying 85% of carriers in the population. If the first partner tested positive, the second partner was screened with an expanded test of another 20 to 30 mutations estimated to identify 90% of carriers. In the end, such an approach identified 75% of anticipated CF births at a cost of $367,000 (1995 dollars) per averted birth. However, this estimate only holds true if "all couples who identify a fetus as high risk choose to terminate the pregnancy. If only half of couples will proceed to abortion under these circumstances, the cost per CF birth avoided would increase to $734,000 per CF birth avoided." 60 Also, "for couples planning two pregnancies, the costeffectiveness ratios for CF screening are roughly half those of the single-pregnancy case," meaning that the cost per CF birth avoided is roughly halved. 60 In 2007, Wei et al. 61 analyzed data collected between 2001 and 2005 on more than 6000 women screened for CF carrier status at the Henry Ford Health System in Detroit, Michigan. Wei et al.'s study complements Asch et al.'s 60 work by providing a more ethnically diverse cohort that was 45% African American, 35% non-Jewish Caucasian, 10% Arab American, 5% Hispanic, 5% Asian, and 1% Ashkenazi Jewish. The study excluded "patients with a family history of CF, a known/ possible diagnosis of CF, males with infertility, and fetuses with echogenic bowels." 61 Approximately, 98.5% of their cohort received sequential screening that included the 25 ACMG recommended mutations in addition to another 7-17 mutations. More than 4 years and at a total cost of $334,000 (2005 dollars), testing identified six positive couples and one (subsequently aborted) fetus with mutations from both parents. Comparing this to a lifetime care cost of $1 million per CF patient, which is within the range indicated by other studies, Wei et al. 61 concluded that population-based carrier screening is cost-effective even when it includes a high number of non-Caucasians. Wei et al.'s 61 cost per CF birth averted is less than Asch et al.'s 60 best-case scenario of $367,000 per averted birth even before the two studies are normalized to same-year dollars.
Rowley et al. 62 used data from a trial of CF carrier screening to analyze cost-effectiveness; 4879 women were tested, 124 of whom were CF carriers but none of whom had pregnancies diagnosed with CF through prenatal testing. Costs (given below) were based on surveys, data from the US Congress's Office of Technology Assessment, and personal communications. Based on those figures and the behaviors observed in the carrier screening trial, Rowley et al. determined the costeffectiveness of screening a hypothetical cohort of 100,000 women. In their model, at a total cost of $11.1 million, 8.4 CF-affected pregnancies were terminated. This translated to $1.322 million to $1.396 million per averted birth, depending on whether parents choose to have another child. Assuming a lifetime care cost of $1.574 million per CF patient, Rowley et al. concluded that "the averted medical-care cost resulting from choices freely made are estimated to offset ϳ74 -78% of the costs of a screening program." 62 The study added that "the cost of prenatal CF carrier screening could fall to equal the averted costs of CF patient care if the cost of carrier testing were to fall to $100." 62 Assuming that a pregnancy is terminated because of CF and the family does not have another pregnancy, there is no gain in terms of aggregate family quality-adjusted life-years (QALYs). If the family has another pregnancy, the marginal cost for prenatal CF carrier screening is estimated to be $8290 per QALY. This figure "is comparable to that for newborn screening for phenylketonuria and is more advantageous than the ratios for many widely advocated preventive interventions." 62 Other reports were considered in an extensive review produced by the Foundation for Blood Research in cooperation with the CDC. 63 Although the review's discussion of previous studies is too extensive to describe here, the review did produce a relevant summary of the financial costs of testing. By using 1996 dollars, the review concluded that diagnosing one case of CF by population screening would cost ϳ$400,000 for Ashkenazi Jewish descendants, $500,000 among non-Hispanic Caucasians, and $19 million among Asian Americans. The $19 million figure reflects the low rate of detecting CF in Asian Americans.
Boston University's panel of 40 mutations (including the ACMG's recommended mutations) for $195 and Ambry's test for ⌬F508 mutations for $85 both show that the market is at least approaching Rowley et al.'s threshold cost of $100 for a cost-effective carrier screening test. Although we cannot estimate overall costs from our price survey, the empirical evidence and empirically derived models discussed above suggest that licensing practices for CFTR at least do not preclude costeffective screening for CF (Table 3) .
Preimplantation genetic diagnosis
Although PGD has been used to detect CF in embryos for more than a decade, there is very limited evidence for its cost-effectiveness. In an oral presentation supported by the Reproductive Genetics Institute and reported in Fertility and Sterility, the cost of performing PGD on 11,511 embryos ($235 million) was compared with the cost of treating CF patients who have been born had PGD not been used to avoid implanting CF-affected embryos (estimated total $50 million annually, based on $55,537 annual direct care costs per patient). 64 The presenters concluded, "Offering IVF-PGD to all CF carrier couples . . . is highly cost-effective and will save hundreds of millions of direct health care dollars annually." 64 Working in Taiwan, Tsai 65 performed PGD "without using fluorescent primers and expensive automatic instrumentation," which was an improvement over previous techniques and a reduction in financial cost. Neither of those sources gives as much empirical evidence as the studies discussed above, leaving PGD's cost-effectiveness open to further research.
LESSONS LEARNED ABOUT THE PATENT PROCESS Research
There is no direct evidence that the patent process affected the research that ultimately led to CFTR gene discovery. The prospect of patents was not reported as an important incentive to do the research, which was largely funded by government and nonprofit entities hoping to understand the disease. Although linkage analysis of the CFTR gene was not successful throughout the 1950s, 13,14 RFLP mapping enabled genetic linkage to chromosome 7 to be established in the 1980s. Researchers identified the first linkage between a marker and the CF phenotype in 1985 and identified the CFTR gene and its most common mutation, ⌬F508, in 1989. 15, 19 Multiple individuals and institutions applied for patents at the same time and the discovery of the CFTR gene was characterized as a "race." 66 However, academic competition more than the prospect of patents incited the intense hunt for the CFTR gene and innovation in techniques for gene mapping and positional cloning of genes, at least among the several academic groups involved. Two primary academic groups (Francis Collins and coworkers, University of Michigan, and John Riordan, Lap-Chee Tsui, and coworkers at the HSC) combined their complementary approaches to advantage and were successful in beating the competition and discovering the CFTR gene in June 1989. Collins, Riordan, and Tsui published their findings simultaneously in three back-to-back articles in September 1989 in Science. As mentioned earlier, they also jointly filed for patents. We have not found any evidence that CF gene patents impeded subsequent basic or clinical research. 63 Providing education and information to the entire population: $1-3 400,000 (Ashkenazi Jewish); 500,000 (non-Hispanic Caucasians); 4,000,000 (Hispanic Caucasians); 7,000,000 (African Americans); and 19,000,000 (Asian Americans)
Development
There is no evidence that the patent process affected the speed of genetic test development. The CF patent interferences were ultimately resolved in 2002, largely in the favor of Tsui and Collins. The interference process took several years to resolve at significant expense. However, it does not appear that the interference proceeding added time to the commercial test development process. It did add costs that were largely borne by one of the patent licensees (who had licensed for therapeutic use such as gene therapy) and not the academic research institutions. During patent inference proceedings, the University of Michigan and the HSC practiced broad, nonexclusive licensing of patents covering mutations including the ⌬F508 mutation. The fact that the NIH Consensus Conference (1997) guidelines recommended genetic testing for all "adults with a positive family history of CF, to partners of people with CF, to couples currently planning a pregnancy, and to couples seeking prenatal testing" and that the 2001 ACMG statement made a similarly broad recommendation for carrier screening suggest that CF genetic test was widely available by the time these reports were released. 49, 50 
Commercialization
Development and commercialization of new test techniques and technologies continue for CF genetic testing. Laboratories use several test methods, platforms, and kits or analyte specific reagents. It is likely that broad and nonexclusive licensing practiced by the University of Michigan, HSC, and JHU has facilitated commercial kit development by lowering IP-related barriers to entry. As of July 2008, 64 laboratories across the country offer CF testing. 11 Patents do not seem to limit overall commercial availability.
Communication/marketing
Direct-to-consumer marketing has not been practiced for CF testing. Marketing and education for CF testing is provided by health professionals within professional associations, among primary care physicians, and among pediatricians. Most laboratories will not perform tests without a doctor's referral. However, as guidelines have called for widespread use of the test, the number of test providers has risen. 1, 26 Although this may increase access, it also means that companies have an incentive to prepare marketing material for patients. In any case, patents and licensing practices have not prevented marketing and publicizing CF testing to date. Nonexclusive licensing may have facilitated growth of the CF genetic testing market.
Adoption
There is no evidence that patents reduced adoption of CF tests by laboratories, health care providers, or third-party payers.
Consumer utilization
There is no evidence that CFTR gene patents and licensing have limited consumer utilization.
CONCLUSION
CF was selected as a case study for this report to the SACGHS as an example of broad nonexclusive licensing of patented genetic tests. Some providers note that gene patents can limit their practice of medicine and, specifically, their ability to provide genetic tests. However, Dr. Debra Leonard notes that "[i]f every license or every patent was being licensed like this cystic fibrosis ⌬F508 mutation," then such constraints on medical practitioners and the associated controversies would be greatly reduced. 67 Our research shows how patenting and licensing decisions by the University of Michigan, the HSC, and JHU allow for significant research without unduly hindering patient access or commercial markets. These practices also preserve strong patent protection and the accompanying investment incentives for possible therapeutic discoveries arising from the same gene sequence. Our study also suggests that the active participation of the CF Foundation (which funded part of the research) 66 in discussions about intellectual property and licensing allowed patient perspectives to be included and may have significantly influenced decisions about licensing. In addition, scientists' perspectives on uncertainties associated with genetic testing in the long-term, especially in light of future discoveries and technological evolution, also helped inform decisions about optimal commercialization strategies. Indeed, the broad, nonexclusive diagnostic licensing practices associated with the patents surrounding CF allow for competition and innovation.
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The case study authors have no consultancies, stock ownership, grants, or equity interests that would create financial conflicts of interest. The Center for Genome Ethics, Law and Policy accepts no industry funding. Dr. Robert Cook-Deegan is listed on the British Medical Journal roster of physicians who have pledged to remain independent of industry funding (http://www.tseed.com/pdfs/bmj.pdf); more details about how the case studies were done are noted in a 29 July 2009 letter to the Secretary's Advisory Committee on Genetics, Health, and Society (http://www.genome.duke.edu/centers/ gelp/documents/SACGHSResponsetopubliccomments.pdf). . "Licensed Patent(s)" shall also include any divisional, continuation (excluding continuations-in-part), reissue, reexamination or extension of the above-described patent applications and resulting patents, along with any extended or restored term, and any confirmation patent, registration patent, or patent of addition. 2.5 "Valid Claim(s)" means any claim(s) in an unexpired patent or pending in a patent application included within the Licensed Patents which has not been held unenforceable, unpatentable, or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed within the time allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer. If in any country there should be two or more such decisions conflicting with respect to the validity of the same claim, the decision of the higher or highest tribunal shall thereafter control; however, should the tribunals be of equal rank, then the decision or decisions upholding the claim shall prevail when the conflicting decisions are equal in number, and the majority of decisions shall prevail when the conflicting decisions are unequal in number. 2.6 "Product(s)" shall mean any product(s) whose manufacture, use or sale in any country would, but for this Agreement, comprise an infringement, including contributory infringement, of one or more Valid Claims. 2.7 "Field of Use" shall refer to the field for which Products may be designed, manufactured, used and/or marketed under this Agreement, and shall mean solely Products to be used for the research of, diagnosis of and screening for the disease cystic fibrosis. 2.8 "Net Sales" shall mean the sum, over the term of this Agreement, of all amounts received and all other consideration received (or, when in a form other than cash or its equivalent, the fair market value thereof when received) by LICENSEE and its Affiliates from persons or entities due to or by reason of the sale or other distribution of Products, or the use of Products, including any use by LICENSEE and Affiliates in the performance of services for their customers; less the following deductions and offsets, but only to the extent such sums are otherwise included in the computation of Net Sales, or are paid by LICENSEE and not otherwise reimbursed: refunds, rebates, replacements or credits actually allowed and taken by purchasers for return of Products; customary trade, quantity and cash discounts actually allowed and taken; excise, value-added, and sales taxes actually paid by LICENSEE for Products; and shipping and handling charges actually paid by LICENSEE for Products. 2.9 "Royalty Quarter(s)" shall mean the three month periods ending on the last day of March, June, September and December of each year.
2.10
"Territory" means all countries of the world. 2.11 "First Diagnostic Sale" shall mean the first sale of any Product (including any sale of a service using a Product in the Field of Use) by LICENSEE or an Affiliate, other than for use in clinical trials being conducted to obtain FDA or other governmental approvals to market Products. 3.
GRANT OF LICENSE. 3.1 MICHIGAN and RDLP hereby grant to LICENSEE a non-exclusive license under the Licensed Patents to make, have made, use (including use in the performance of services for its customers), market and sell, in the Territory, Products designed and marketed solely for use in the Field of Use. 3.2 MICHIGAN and RDLP reserve the right to license and use all aspects of the TECHNOLOGY and the Licensed Patents for any use or purpose, including the right to develop and produce Products.
3.3
The license granted to LICENSEE herein shall be without the right to sublicense, except that LICENSEE may sublicense Affiliate(s) who agree to be and are bound in writing to the terms and conditions of this Agreement to the same extent as LICENSEE. LICENSEE agrees to strictly monitor and enforce compliance with the terms and conditions of this Agreement by all Affiliate sublicensees. The obligation to pay MICHIGAN a royalty under this Article 4 is imposed only once with respect to the same unit of Product regardless of the number of Valid Claims or Licensed Patents covering the same; however, for purposes of determination of payments due hereunder, whenever the term "Product" may apply to a property during various stages of manufacture, use or sale, Net Sales, as otherwise defined, shall be derived from the sale, distribution or use of such Product by LICENSEE or Affiliates at the stage of its highest invoiced value to unrelated third parties. 4.4 LICENSEE shall pay to MICHIGAN an annual license maintenance fee. This annual fee shall accrue in the Royalty Quarter ending in March of the years specified below, and shall be due and payable and included with the report for that quarter.
If LICENSEE defaults in the payment of any annual license maintenance fee, and fails to remedy that default within sixty (60) days after written notice of it by MICHIGAN, then this Agreement and the license rights conveyed herein shall terminate.
The annual license maintenance fees shall be as follows: (1) In 2005, and in each year thereafter during the term of this Agreement up to and including the year in which LICENSEE first obtains FDA approval or other governmental approval to distribute or use Products in the Field of Use: U.S. $18,000.00; Also, notwithstanding (1) above (and in place of the amounts therein listed, when applicable): (2) In the first calendar year following the year in which LICENSEE obtains the approval described in (1) above, and in each year thereafter during the term of this Agreement up to and including the year in which the First Diagnostic Sale occurs: U.S. $20,000.00; Also, notwithstanding (1-2) above (and in place of the amounts therein listed, when applicable): (3) In the first calendar year following the First Diagnostic Sale: U.S. $20,000.00; (4) In the second year following the First Diagnostic Sale: U.S. $22,500.00; (5) In the third year following the First Diagnostic Sale: U.S. $25,000.00; and (6) In the fourth year following the First Diagnostic Sale, and in each year thereafter during the term of this Agreement; U.S. $30,000.00. Each annual fee paid under (3-6) above may be credited by LICENSEE in full against all earned royalties otherwise to be paid to MICHIGAN under Paragraph 4.2 for the calendar year in which the specific annual fee is paid. The year for which such credits against royalties may be taken includes the Royalty Quarter in which the annual fee accrues and the next three Royalty Quarters. Each annual fee paid under (1-2) above may be credited by LICENSEE in full against all earned royalties otherwise to be paid to MICHIGAN under Paragraph 4.2 after such annual fee is paid. 4.5 If LICENSEE takes any license(s), in a given country, under valid third party patents which would be infringed by the manufacture, use or sale of Products in that country, then LICENSEE can deduct up to forty percent (40%) of the royalties otherwise due and payable in each Royalty Quarter under Paragraph 4.2 above for Net Sales in that country, until such time as LICENSEE has recovered an amount equal to forty percent (40%) of the royalty paid to such third parties; provided that in no event shall such deducted amounts be applied to reduce or require reimbursement of the annual fees required under Paragraph 4.4. This Paragraph is not intended to imply an obligation upon MICHIGAN or RDLP to reimburse LICENSEE's above-described third-party royalties; the rights granted to LICENSEE in this Paragraph shall not exceed the ability of the above-described mechanism (i.e., a deduction of 40% of royalties due upon Net Sales in the country in question) to reimburse such expenses. LICENSEE shall make an accounting to MICHIGAN of all such thirdparty royalties, and all resulting deductions from royalties otherwise due and payable to MICHIGAN, as part of its reporting obligations under Article 5 below.
4.6
If MICHIGAN and RDLP grant a license under the Licensed Patents and in the Field of Use to any third party which is substantially the same as the license granted to LICENSEE under Article 3 above, for all or any part of the Territory, but which requires a royalty rate or license maintenance fees lower than those required of LICENSEE under this Agreement, then MICHIGAN and RDLP shall offer those terms to LICENSEE for that part of the Territory, to be effective as of the effective date of the license to that third party. 5.
REPORTS.
5.1
Within sixty (60) days after the close of (i) any Royalty Quarter in which a fee under Paragraph 4.4 accrues, and (ii) each Royalty Quarter following the First Diagnostic Sale during the term of this Agreement (including the close of any Royalty Quarter immediately following any termination of this Agreement), LICENSEE shall report to MICHIGAN all royalties accruing to MICHIGAN during such Royalty Quarter. Such quarterly reports shall indicate for each Royalty Quarter the gross sales and Net Sales of Products by LICENSEE and Affiliates, and any other revenues with respect to which payments are due, and the amount of such payments, as well as the various calculations used to arrive at said amounts, including the quantity, description (nomenclature and type designation), country of manufacture and country of sale of Products. In case no payment is due for any such period, LICENSEE shall so report. 5.2 LICENSEE covenants that it will promptly establish and consistently employ a system of specific nomenclature and type designations for Products so that various types can be identified and segregated, where necessary; LICENSEE and Affiliates shall consistently employ such system when rendering invoices thereon and henceforth agree to inform MICHIGAN, or its auditors, when requested as to the details concerning such nomenclature system as well as to all additions thereto and changes therein. 5.3 LICENSEE shall keep, and shall require its Affiliates to keep, true and accurate records and books of account containing data reasonably required for the computation and verification of payments to be made as provided by this Agreement, which records and books shall be open for inspection upon reasonable notice during business hours by an independent certified accountant selected by MICHIGAN, for the purpose of verifying the amount of payments due and payable. Said right of inspection will exist for six (6) years from the date of origination of any such record, and this requirement and right of inspection shall survive any termination of this Agreement. MICHIGAN shall be responsible for all expenses of such inspection, except that if such inspection reveals an underpayment of royalties to MICHIGAN in excess of ten percent (10%) for any year, then said inspection shall be at LICENSEE's expense and such underpayment shall become immediately due and payable to MICHIGAN.
5.4
The reports provided for hereunder shall be certified by an authorized representative of LICENSEE to be correct to the best of LICENSEE's knowledge and information. 6.
TIMES If LICENSEE shall at any time default in the payment of any royalty or the making of any report hereunder, or shall make any false report, or shall commit any material breach of any covenant or promise herein contained, and shall fail to remedy any such default, breach or report within sixty (60) days after written notice thereof by MICHIGAN specifying such default, then MICHIGAN and RDLP may, at their option, terminate this Agreement and the license rights granted herein by notice in writing to such effect. Any such termination shall be without prejudice to any Party's other legal rights for breach of this Agreement. 12. 4 LICENSEE may terminate this Agreement by giving MICHIGAN a notice of termination, which shall include a statement of the reasons, whatever they may be, for such termination and the termination date established by LICENSEE, which date shall not be sooner than ninety (90) days after the date of the notice. Such notice shall be deemed by the Parties to be final. 12.5
In the event LICENSEE shall at any time during the term of this Agreement deal with the TECHNOLOGY or Products in any manner which violates the laws, regulations or similar legal authority of any jurisdiction including, but not limited to, the public health requirements relating to the TECHNOLOGY or Products or the design, development, manufacture, offering for sale, sale or other disposition of Products, the license granted herein shall terminate immediately with respect to such Products within the territory encompassed by such jurisdiction. 13.
ASSIGNMENT. Due to the unique relationship between the Parties, this Agreement shall not be assignable by LICENSEE without the prior written consent of MICHIGAN and RDLP. Any attempt to assign this Agreement without such consent shall be void from the beginning. MICHIGAN and RDLP shall not unreasonably withhold consent for LICENSEE to assign this Agreement to a purchaser of all or substantially all of LICENSEE's business. No assignment shall be effective unless and until the intended assignee agrees in writing with RDLP and MICHIGAN to accept all of the terms and conditions of this Agreement. Further, LICENSEE shall refrain from pledging any of the license rights granted in this Agreement as security for any creditor. 14.
REGISTRATION AND RECORDATION. 14.1
If the terms of this Agreement, or any assignment or license under this Agreement are or become such as to require that the Agreement or license or any part thereof be registered with or reported to a national or supranational agency of any area in which LICENSEE or Affiliates would do business, LICENSEE will, at its expense, undertake such registration or report. Prompt notice and appropriate verification of the act of registration or report or any agency ruling resulting from it will be supplied by LICENSEE to MICHIGAN. 14. PUBLICITY. LICENSEE agrees to refrain from using and to require Affiliates to refrain from using the name of MICHIGAN, HHMI, RDLP and HSC in publicity or advertising without the prior written approval of that entity. 18.
PRODUCT MARKING. LICENSEE agrees to mark, and to require Affiliates to mark, Products with the appropriate patent notice as approved by MICHIGAN or RDLP (when appropriate), such approval not to be unreasonably withheld. 19 .
NOTICES. Any notice, request, report or payment required or permitted to be given or made under this Agreement by a Party shall be given by sending such notice by certified or registered mail, return receipt requested, to the address set forth below or such other address as such Party shall have specified by written notice given in conformity herewith. Any notice not so given shall not be valid unless and until actually received, and any notice given in accordance with the provisions of this Paragraph shall be effective when mailed. : INVALIDITY.
In the event that any term, provision, or covenant of this Agreement shall be determined by a court of competent jurisdiction to be invalid, illegal or unenforceable, that term will be curtailed, limited or deleted, but only to the extent necessary to remove such invalidity, illegality or unenforceability, and the remaining terms, provisions and covenants shall not in any way be affected or impaired thereby. 21.
ENTIRE AGREEMENT AND AMENDMENTS. This Agreement contains the entire understanding of the Parties with respect to the matter contained herein. The Parties may, from time to time during the continuance of this Agreement, modify, vary or alter any of the provisions of this Agreement, but only by an instrument duly executed by authorized officials of all Parties hereto. 22.
WAIVER.
No waiver by a Party of any breach of this Agreement, no matter how long continuing or how often repeated, shall be deemed a waiver of any subsequent breach thereof, nor shall any delay or omission on the part of a Party to exercise any right, power, or privilege hereunder be deemed a waiver of such right, power or privilege. 23.
ARTICLE HEADINGS. The Article headings herein are for purposes of convenient reference only and shall not be used to construe or modify the terms written in the text of this Agreement. 24 .
NO AGENCY RELATIONSHIP. The relationship between the Parties is that of independent contractor and contractees. LICENSEE shall not be deemed to be an agent of MICHIGAN or RDLP in connection with the exercise of any rights hereunder, and shall not have any right or authority to assume or create any obligation or responsibility on behalf of MICHIGAN or RDLP.
